Hosted on MSN1mon
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD
Bluebird Bio (BLUE) announced new and updated data from LYFGENIA gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events. As of July 2024, 70 patients were ...
Opinion: The revolutionary sickle cell therapies
In December, the US Food and Drug Administration (FDA) approved the first two cell-based gene therapies for treating sickle ...
Managed Healthcare Executive1d
CMS Cell and Gene Therapy Access Plan Earns Reprieve After Trump Halt
President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...
pharmaphorum4d
FDA clears two sickle-cell gene therapies, including CRISPR first
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...
Yahoo1mon
Gene therapy uptake in sickle cell stays slow, despite patient interest
Slow beginnings for new medicines, especially ones as complex as Casgevy and Lyfgenia, aren’t anything new in the pharmaceutical industry. But the plodding uptake over the therapies’ first ...
Forbes1mon
Biden Administration’s Access Model Offers Hope For Cell And Gene Therapies
Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. The Biden Administration announced this week that the manufacturers of ...